Tales from the Trenches: Paul Edick, CEO of Xeris
After a remarkable career in biopharma, Paul Edick was enjoying retirement. Then he got the call to become CEO of Xeris Pharmaceuticals.
Tuesday, April 23, 2019
5:30 PM - 7:00 PM (Central Standard Time)
222 Merchandise Mart Plaza Suite 1230 Chicago, IL 60654 Get Directions
After a remarkable career in biopharma, Paul Edick was enjoying retirement. Then he got the call to become CEO of Xeris Pharmaceuticals. Drawn to the organization’s technology and mission, Paul agreed to take Xeris’ helm in 2017. With Xeris, Paul has again achieved remarkable success: Since 2017, Xeris has raised over $200M in capital (including taking the company public); completed several preclinical and clinical studies; established new corporate headquarters in downtown Chicago; built a state-of-the-art lab in San Diego and grown its staff to over 100 employees.
This summer, the company will commercialize its first product, which delivers the life-saving hormone glucagon to people with diabetes who experience a severe sudden drop in blood sugar.
About the Speaker:
Paul Edick is chairman and CEO of Xeris Pharmaceuticals (Nasdaq: XERS), a private technology-based company with an initial focus on therapies for diabetes-associated hypoglycemia. Prior to Xeris, Paul was founding partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Paul served as CEO of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Paul was the CEO of Ganic Pharmaceuticals and MedPointe Healthcare.
Paul also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations including Pharmacia and Searle Pharmaceuticals, as well as leading the U.S. managed care organization, U.S. marketing organization and Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. In addition, Paul has also held sales, marketing, advertising and advisory positions with Procter & Gamble, Ortho Pharmaceuticals and The Hamilton Group.
Paul currently serves as the chairman of the Board of Iterum Therapeutics. Paul has also previously served on a number of pharmaceutical and healthcare company boards, including PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals plc (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications. He was also chairman of the Board of Life Cycle Pharma Ltd (fka Veloxis).